

MSTCVS Quality Collaborative 2023 VBR Quality Improvement Initiatives Final Report

Due to the Coordinating Center October 20, 2023

| Hospital Name: | |
|----------------|--|
| Submitted by: | |
| Date: | |

2023 MSTCVS VBR Measure #1

*Reimbursement will not be awarded without evidence that a plan was implemented and/or if no reports are submitted

| VBR Quality Initiative: | Multiple Arterial Grafting | | | |
|---|----------------------------|--|--|--|
| Target Patient Population: | Isolated CABG | | | |
| Information related to this VBR measure will be reported on the MSTCVS P4P QI Initiatives Progress Report | | | | |

2023 MSTCVS VBR Measure #2

| *Reimbursement will not be awarded without evidence that a plan was implemented and/or if no reports are submitted | | | | | | | |
|--|--|----------|----------|----------------|--|--|--|
| VBR Quality Initiative: | Percentage of patients with intraoperative peak glucose <180 mg/dl | | | | | | |
| Target Patient Population: | Isolated CABG | | | | | | |
| Baseline Data: | | | | | | | |
| 2023 Goal: | 75% | | | | | | |
| Results: | Q1 2023: | Q2 2023: | Q3 2023: | Jan-Sept 2023: | | | |
| Was the progress of this QI reviewed by a multidisciplinary team? If yes, please list disciplines: | | | | | | | |
| Please describe all interventions and strategies and when they were implemented: | | | | | | | |
| Please describe any challenges or barriers that were encountered and how your team overcame them: | | | | | | | |
| Additional information, comments, or observations: | | | | | | | |

For assistance completing this form, contact Melissa Clark: <u>clarkmel@med.umich.edu</u> Return completed form to Barbara Benedetti: <u>bbenedet@med.umich.edu</u>

| 2023 MSTCVS VBR Measure #3 *Reimbursement will not be awarded without evidence that a plan was implemented and/or if no reports are submitted | | | | | | | |
|--|--|----------|----------|----------------|--|--|--|
| VBR Quality Initiative: | Percentage of patients with myocardial infarction within 21 days prior to surgery with dual antiplatelets ordered at discharge | | | | | | |
| Target Patient Population: | Isolated CABG | | | | | | |
| Baseline Data: | | | | | | | |
| 2023 Goal: | 90% | | | | | | |
| Results: | Q1 2023: | Q2 2023: | Q3 2023: | Jan-Sept 2023: | | | |
| Was the progress of this QI reviewed by a multidisciplinary team? If yes, please list disciplines: Please describe all interventions and strategies and when they were implemented: | | | | | | | |
| Please describe any challenges or barriers that were encountered and how your team overcame them: | | | | | | | |
| Additional information, comments, or observations: | | | | | | | |